Trial Profile
Efficacy and cost effectiveness of moxifloxacin versus cefotaxime +/- macrolides for the treatment of patients with community-acquired pneumonia in Russia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2012
Price :
$35
*
At a glance
- Drugs Amoxicillin/clavulanic acid (Primary) ; Amoxicillin/clavulanic acid (Primary) ; Cefotaxime (Primary) ; Ceftriaxone (Primary) ; Moxifloxacin (Primary) ; Moxifloxacin (Primary) ; Azithromycin; Clarithromycin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Bayer HealthCare Pharmaceuticals
- 26 Jun 2012 Additional treatment groups/descriptors added, patient numbers updated to 167, and treatment details updated/added
- 06 Jun 2012 Updated results presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 Nov 2011 New trial record